Your SlideShare is downloading. ×
Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala


Published on

Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala

Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala

Published in: Law, Technology
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Biotechnology and IP By Dr. Kalyan Kankanala Blog:
  • 2. US Patent Law and Biotechnology
  • 3. Overview • Article 1 Section 1 Clause 8 • Quid Pro Quo • Incentives • Title 35 • •
  • 4. Patentability requirements • Patentable subject matter • Utility • Novelty • Nonobviousness • Specification
  • 5. INVENTIONS Subject Matter Usefulness Novelty Non-obviousness Specification PATENTS Kalyan’s Patent Filter Model
  • 6. Patentable Subject Matter • Section 101 - Process, machine, manufacture, composition of matter and Improvements • Funk Bros. v. Kalo • Diamond v. Chakrabarty • Pioneer Hibebred v. J.E.M. Arguments and Issues
  • 7. Funk Bros • Rhizobium bacteria • Innoculum of mutually inhibiting bacteria • Is it a product of nature?
  • 8. Chakrabarty's case • Psuedomonas bacteria • Four different plasmids inserted. • Is it a product of Nature?
  • 9. Utility • Current • Substantial • Credible • Brenner v. Manson • Gene/protein sequences
  • 10. Novelty • Section 102 • Known or used • Patented or published • Public use or On sale • Abandoned • Foreign Priority • Patented in another country
  • 11. Novelty • Derived • Suppressed or Concealed • Diligence • Single prior art reference • Isolated or purified- activity • Hybritech v. Monoclonal
  • 12. Nonobviousness • Scope of prior art • Differences- invention and prior art • Level of ordinary skill • Secondary Indicia • At the time of conception • Obvious to try
  • 13. Hybritech v. Monoclonal • immunometric assays using monoclonal antibodies
  • 14. Prior Art • a. Kohler and Milstein's Nobel Prize-Winning Work for Producing Monoclonal antibodies in vitro; • b. The Work of Drs. Oi and Herzenberg, in which they used monoclonal antibodies to "map" epitopes or determine the number and location of different antibody binding sites on a known quantity of IgE antigen by attaching to it an antibody bound to a carrier and exposing that antigen to other monoclonal antibodies; • c. The Frankel Article that disclosed Monoclonal Antibodies Having Affinities of 109 liters/mole; and • d. Articles "Predicting" Widespread Use of Monoclonal antibodies.
  • 15. In re Deuel: • Isolated and purified DNA and cDNA sequences encoding heparin-binding growth factors ("HBGFs")
  • 16. Prior Art • Bohlen's patent application disclosed a group of protein growth factors designated as heparin-binding brain mitogens ("HBBMs") useful in treating burns and promoting the formation, maintenance, and repair of tissue, particularly neural tissue. Bohlen determined the first 19 amino acids of the proteins' N- terminal sequences, which were found to be identical for human and bovine HBBMs. He provided no teachings concerning DNA or cDNA coding for HBBMs in his application.
  • 17. Prior Art • Maniatis described a method of isolating DNAs or cDNAs by screening a DNA or cDNA library with a gene probe. The reference outlined a general technique for cloning a gene but did not describe how to isolate a particular DNA or cDNA molecule.
  • 18. Recent Developments • KSR Vs. Teleflex • In re Kubin
  • 19. Specification • Written Description • Enablement • Best Mode • Claims • Object: Notice and Dissemination
  • 20. Example • A stent coated with taxol for "treating or preventing recurrent stenosis. • Prior ArtStents Existing • Taxol known for Tumor treatment by angiogenesis • Article - Re-stenosis dangers and need for a treatment - suggests various options
  • 21. Have a nice day For more information: Email: